A phase 1 study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma. Non-blind dosage gradual increase study

Trial Profile

A phase 1 study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma. Non-blind dosage gradual increase study

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Fluorouracil (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 01 Jun 2017 Results published in the Drugs in R and D
    • 20 Dec 2011 New trial record
    • 01 Sep 2011 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top